CN1616381A - 一种灯盏细辛有效组分的制备方法 - Google Patents
一种灯盏细辛有效组分的制备方法 Download PDFInfo
- Publication number
- CN1616381A CN1616381A CN 200310113536 CN200310113536A CN1616381A CN 1616381 A CN1616381 A CN 1616381A CN 200310113536 CN200310113536 CN 200310113536 CN 200310113536 A CN200310113536 A CN 200310113536A CN 1616381 A CN1616381 A CN 1616381A
- Authority
- CN
- China
- Prior art keywords
- acid
- preparation
- alcohol
- herba erigerontis
- dilute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001013934 Erigeron breviscapus Species 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 238000000605 extraction Methods 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930003944 flavone Natural products 0.000 claims abstract description 12
- 235000011949 flavones Nutrition 0.000 claims abstract description 12
- 239000004952 Polyamide Substances 0.000 claims abstract description 10
- 229920002647 polyamide Polymers 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 241000132521 Erigeron Species 0.000 claims abstract description 5
- 239000003513 alkali Substances 0.000 claims abstract description 5
- 238000001179 sorption measurement Methods 0.000 claims abstract description 5
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 claims description 25
- 229940031826 phenolate Drugs 0.000 claims description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 22
- 150000007965 phenolic acids Chemical class 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 16
- 238000001556 precipitation Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 15
- 150000007513 acids Chemical class 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 150000002213 flavones Chemical class 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 239000000470 constituent Substances 0.000 claims description 10
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 8
- 239000012675 alcoholic extract Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 235000012054 meals Nutrition 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 5
- 235000016213 coffee Nutrition 0.000 claims description 5
- 235000013353 coffee beverage Nutrition 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 229960000948 quinine Drugs 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 claims description 3
- 229930190376 scutellarin Natural products 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 2
- 235000008714 apigenin Nutrition 0.000 claims description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 2
- 229940117893 apigenin Drugs 0.000 claims description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 2
- 229940074393 chlorogenic acid Drugs 0.000 claims description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- 150000008131 glucosides Chemical class 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- UFCLZKMFXSILNL-BKUKFAEQSA-N 3,4-di-O-caffeoylquinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O UFCLZKMFXSILNL-BKUKFAEQSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 7
- 239000002904 solvent Substances 0.000 abstract description 5
- VEYIMQVTPXPUHA-UHFFFAOYSA-N 3-hydroxypyran-4-one Chemical compound OC1=COC=CC1=O VEYIMQVTPXPUHA-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000747 cardiac effect Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 238000007670 refining Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 abstract 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 150000002212 flavone derivatives Chemical class 0.000 abstract 1
- 231100000784 hepatotoxin Toxicity 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 23
- 239000007788 liquid Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000005406 washing Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000019219 chocolate Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101800004637 Communis Proteins 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- -1 4-O- Chemical compound 0.000 description 1
- 241000189115 Catananche Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical class O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229950009125 cynarine Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101135366A CN1326814C (zh) | 2003-11-14 | 2003-11-14 | 一种灯盏细辛有效组分的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101135366A CN1326814C (zh) | 2003-11-14 | 2003-11-14 | 一种灯盏细辛有效组分的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1616381A true CN1616381A (zh) | 2005-05-18 |
CN1326814C CN1326814C (zh) | 2007-07-18 |
Family
ID=34759969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101135366A Expired - Fee Related CN1326814C (zh) | 2003-11-14 | 2003-11-14 | 一种灯盏细辛有效组分的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1326814C (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100457132C (zh) * | 2006-11-30 | 2009-02-04 | 浙江大学 | 一种灯盏细辛浸膏干燥物的制备方法 |
CN101632724B (zh) * | 2008-07-25 | 2012-03-28 | 贵州益佰制药股份有限公司 | 荭草和灯盏细辛组合物在制备治疗脑血管及相关疾病药物中的应用 |
CN103877111A (zh) * | 2014-03-25 | 2014-06-25 | 云南植物药业有限公司 | 一种灯盏花黄酮药物组合物及其制备方法 |
CN103965274A (zh) * | 2013-02-05 | 2014-08-06 | 河北以岭医药研究院有限公司 | 一种芹菜素-7-o-β-D-葡萄糖醛酸苷制备方法及用途 |
CN104415046A (zh) * | 2013-08-30 | 2015-03-18 | 河北以岭医药研究院有限公司 | 一种芹菜素-7-o-β-D-葡萄糖醛酸苷的应用 |
CN105646620A (zh) * | 2015-12-29 | 2016-06-08 | 云南生物谷药业股份有限公司 | 灯盏花甲素的制备方法 |
CN107312048A (zh) * | 2017-06-05 | 2017-11-03 | 刘祖洪 | 一种灯盏花素粗品的水提方法 |
CN107334813A (zh) * | 2017-07-19 | 2017-11-10 | 力致(厦门)生物科技有限公司 | 一种四方蒿提取物及其制法和用途 |
CN111956678A (zh) * | 2020-08-31 | 2020-11-20 | 李振珲 | 一种多舌飞蓬属植物中活性成分及其提取方法 |
WO2022135329A1 (zh) * | 2020-12-21 | 2022-06-30 | 云南生物谷药业股份有限公司 | 含有灯盏细辛、人参、麦冬、五味子的药物组合物 |
WO2022135330A1 (zh) * | 2020-12-21 | 2022-06-30 | 云南生物谷药业股份有限公司 | 一种药物组合物的制备方法 |
CN114681563A (zh) * | 2020-12-29 | 2022-07-01 | 云南生物谷药业股份有限公司 | 含有灯盏细辛、人参、麦冬、五味子的药物组合物 |
CN114699437A (zh) * | 2020-12-29 | 2022-07-05 | 云南生物谷药业股份有限公司 | 含有灯盏细辛提取物的口服制剂及其制备方法 |
WO2022143252A1 (zh) * | 2020-12-29 | 2022-07-07 | 云南生物谷药业股份有限公司 | 一种药物组合物的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1032405A (zh) * | 1987-09-29 | 1989-04-12 | 史延令 | 拨珠式输入装置 |
CN1053609A (zh) * | 1990-01-25 | 1991-08-07 | 云南省生物制药厂 | 灯盏花素片剂原料药的提取工艺 |
CN1327811A (zh) * | 2000-06-12 | 2001-12-26 | 中国科学院昆明植物研究所 | 灯盏花有效部位及制备工艺和制剂 |
-
2003
- 2003-11-14 CN CNB2003101135366A patent/CN1326814C/zh not_active Expired - Fee Related
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100457132C (zh) * | 2006-11-30 | 2009-02-04 | 浙江大学 | 一种灯盏细辛浸膏干燥物的制备方法 |
CN101632724B (zh) * | 2008-07-25 | 2012-03-28 | 贵州益佰制药股份有限公司 | 荭草和灯盏细辛组合物在制备治疗脑血管及相关疾病药物中的应用 |
CN103965274A (zh) * | 2013-02-05 | 2014-08-06 | 河北以岭医药研究院有限公司 | 一种芹菜素-7-o-β-D-葡萄糖醛酸苷制备方法及用途 |
CN104415046A (zh) * | 2013-08-30 | 2015-03-18 | 河北以岭医药研究院有限公司 | 一种芹菜素-7-o-β-D-葡萄糖醛酸苷的应用 |
CN104415046B (zh) * | 2013-08-30 | 2019-03-05 | 河北以岭医药研究院有限公司 | 一种芹菜素-7-o-β-D-葡萄糖醛酸苷的应用 |
CN103877111A (zh) * | 2014-03-25 | 2014-06-25 | 云南植物药业有限公司 | 一种灯盏花黄酮药物组合物及其制备方法 |
CN105646620A (zh) * | 2015-12-29 | 2016-06-08 | 云南生物谷药业股份有限公司 | 灯盏花甲素的制备方法 |
CN105646620B (zh) * | 2015-12-29 | 2018-06-26 | 云南生物谷药业股份有限公司 | 灯盏花甲素的制备方法 |
CN107312048A (zh) * | 2017-06-05 | 2017-11-03 | 刘祖洪 | 一种灯盏花素粗品的水提方法 |
CN107334813A (zh) * | 2017-07-19 | 2017-11-10 | 力致(厦门)生物科技有限公司 | 一种四方蒿提取物及其制法和用途 |
CN111956678A (zh) * | 2020-08-31 | 2020-11-20 | 李振珲 | 一种多舌飞蓬属植物中活性成分及其提取方法 |
WO2022135329A1 (zh) * | 2020-12-21 | 2022-06-30 | 云南生物谷药业股份有限公司 | 含有灯盏细辛、人参、麦冬、五味子的药物组合物 |
WO2022135330A1 (zh) * | 2020-12-21 | 2022-06-30 | 云南生物谷药业股份有限公司 | 一种药物组合物的制备方法 |
CN114681563A (zh) * | 2020-12-29 | 2022-07-01 | 云南生物谷药业股份有限公司 | 含有灯盏细辛、人参、麦冬、五味子的药物组合物 |
CN114699437A (zh) * | 2020-12-29 | 2022-07-05 | 云南生物谷药业股份有限公司 | 含有灯盏细辛提取物的口服制剂及其制备方法 |
WO2022143513A1 (zh) * | 2020-12-29 | 2022-07-07 | 云南生物谷药业股份有限公司 | 含有灯盏细辛提取物的口服制剂及其制备方法 |
WO2022143514A1 (zh) * | 2020-12-29 | 2022-07-07 | 云南生物谷药业股份有限公司 | 含有咖啡酸酯和灯盏花素的口服制剂及其制备方法 |
WO2022143251A1 (zh) * | 2020-12-29 | 2022-07-07 | 云南生物谷药业股份有限公司 | 含有灯盏细辛、人参、麦冬、五味子的药物组合物 |
WO2022143252A1 (zh) * | 2020-12-29 | 2022-07-07 | 云南生物谷药业股份有限公司 | 一种药物组合物的制备方法 |
CN115518123A (zh) * | 2020-12-29 | 2022-12-27 | 云南生物谷药业股份有限公司 | 一种药物组合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1326814C (zh) | 2007-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1326814C (zh) | 一种灯盏细辛有效组分的制备方法 | |
CN101040901A (zh) | 迷迭香提取物及其制备方法和应用 | |
CN101537039A (zh) | 一种香青兰总黄酮提取物及其制备方法与应用 | |
CN1931236B (zh) | 一种由丹参和红景天制成的药物组合物 | |
CN102771593A (zh) | 一种降血糖、血脂、血压的藤茶制剂及其制备方法 | |
CN103006838A (zh) | 一种治疗心脑血管疾病的中药组合物 | |
CN107412430A (zh) | 一种玄参水提物及其应用 | |
CN1943569B (zh) | 一种中药活性成分组合物及其制备方法和用途 | |
CN1112198C (zh) | 叶下珠及同属植物醇提物的制药中的应用 | |
CN1173707C (zh) | 一种含野黄芩甙和咖啡酰奎宁酸的药用组合物 | |
KR101228920B1 (ko) | 황칠나무 잎 추출물을 유효성분으로 함유하는 장질환 치료 및 예방을 위한 조성물 | |
KR20130130580A (ko) | 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 및 그 제조 방법 | |
CN103405501B (zh) | 三味活血化瘀胶囊的制取方法 | |
CN101856357B (zh) | 救必应酸在制备防治心脑血管疾病的药物中的应用 | |
CN101342236B (zh) | 丹参提取物的制法、丹参提取物和含有其的药物组合物 | |
CN106581109A (zh) | 一种用于治疗脑血栓的药物组合物 | |
CN102716231B (zh) | 一种治疗脑损伤和脑水肿的中药组合物及其应用 | |
CN105287659B (zh) | 含有奎尼酸类及糖苷类化合物的檵木提取物及其医药用途 | |
CN101966196A (zh) | 梓葛注射液及粉针的处方及制备方法 | |
CN101744938B (zh) | 一种药物组合物及其制备方法 | |
CN100400074C (zh) | 一种治疗冠心病、脑动脉硬化的中药制剂及其制备方法 | |
CN101176751B (zh) | 丹参和桂枝的药物组合物 | |
CN102838485B (zh) | 一种大叶冬青提取物 | |
CN101884666A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 | |
CN1182867C (zh) | 一种治疗脑中风后遗症的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN JINSHAJIANG INVESTMENT CO., LTD. Free format text: FORMER OWNER: SHENGWUGU SCIENCE AND TECHNOLOGY CO LTD, SHENZHEN CITY Effective date: 20100830 Free format text: FORMER OWNER: SHENZHEN BIOLOGICAL VALLEY MEDICAL RESEARCH INSTITUTE CO., LTD. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100830 Address after: 518026, Guangdong, Futian District, Yitian Road, Jiangsu building, 34 floor, Shenzhen Patentee after: Shenzhen Biovalley Technology Co., Ltd. Address before: 518026, Guangdong, Futian District, Yitian Road, Jiangsu building, 34 floor, Shenzhen Co-patentee before: Shenzhen biological Valley Medicine Research Institute Co Ltd Patentee before: Shengwugu Science and Technology Co., Ltd., Shenzhen City |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050518 Assignee: YUNNAN BIOVALLEY PHARMACEUTICAL CO., LTD. Assignor: Shenzhen Biovalley Technology Co., Ltd. Contract record no.: 2015530000021 Denomination of invention: Process for preparing Erigeron breviscapus active component Granted publication date: 20070718 License type: Exclusive License Record date: 20150326 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Shenzhen Biovalley Technology Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Shenzhen Biovalley Technology Co., Ltd. Document name: Notification of Termination of Patent Right |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070718 Termination date: 20161114 |